{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:59Z","timestamp":1794565559506,"version":"4.9.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Placenta accreta spectrum (PAS) is a serious pregnancy condition compromising the trophoblastic invasion of the placenta or part of it into the myometrium. It is mainly treated by hysterectomy which may leave many complications on the long term mainly infertility. Nonetheless, the desire to preserve fertility has prompted investigation into fertility-preserving alternatives, most notably the off-label use of methotrexate, despite limited consensus on its efficacy or safety. The aim of this review is to assess the efficacy of methotrexate in treating PAS based on pregnancy trimesters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A search of different databases was performed, extracting the relevant information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion:<\/jats:title>\n                    <jats:p>This part is divided into two major parts: the use of methotrexate alone and the use of combination therapies including methotrexate. The former was mainly used in the third trimester according to the selected literature, and postpartum while the latter was used in different trimesters. Out of 27 articles, 63% demonstrated a favorable response to methotrexate. However, the outcome has shown no change between different gestational ages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Despite guideline recommendations, methotrexate may serve as a viable conservative option in carefully selected hemodynamically stable patients, warranting further investigation. Further large-scale studies stratified by trimester or patient population are needed to assess its safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003524","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T17:00:49Z","timestamp":1756832449000},"page":"5637-5643","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The use of methotrexate in the management of placenta accreta spectrum: a narrative review"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-4632","authenticated-orcid":false,"given":"Lea","family":"Nohra","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Nafeh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Balamand, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Assi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lebanese American University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"El Chbib","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Saint Joseph, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"R1-20251007","doi-asserted-by":"crossref","first-page":"1045\u201349","DOI":"10.1016\/j.ajog.2005.06.037","article-title":"Placenta previa-accreta: risk factors and complications","volume":"193","author":"Usta","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20251007","doi-asserted-by":"crossref","first-page":"907\u201313","DOI":"10.1111\/jog.13590","article-title":"Retrospective analysis: conservative treatment of placenta increta with methotrexate","volume":"44","author":"Zhang","year":"2018","journal-title":"J Obstet Gynaecol Res"},{"key":"R3-20251007","doi-asserted-by":"crossref","first-page":"1259\u201364","DOI":"10.1007\/s00404-014-3573-1","article-title":"Methotrexate management for placenta accreta: a prospective study","volume":"291","author":"Lin","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"R4-20251007","first-page":"221\u201324","article-title":"Partial placenta increta and methotrexate therapy: three case reports","volume":"35","author":"Pinho","year":"2008","journal-title":"Clin Exp Obstet Gynecol"},{"key":"R5-20251007","doi-asserted-by":"crossref","first-page":"844\u201351","DOI":"10.1111\/1756-185X.12862","article-title":"Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story","volume":"19","author":"Malaviya","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"R6-20251007","doi-asserted-by":"crossref","first-page":"731\u201342","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R7-20251007","doi-asserted-by":"crossref","first-page":"399\u2013400","DOI":"10.1111\/jcpt.13120","article-title":"Methotrexate for placenta accreta spectrum disorders: is it needed?","volume":"45","author":"Matsubara","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R8-20251007","first-page":"263\u201367","article-title":"Placenta accreta spectrum: conservative management and its impact on future fertility","volume":"3","author":"Abbas","year":"2021","journal-title":"Matern-Fetal Med Online"},{"key":"R9-20251007","doi-asserted-by":"crossref","first-page":"755\u201360","DOI":"10.1016\/j.ajog.2015.04.034","article-title":"Conservative management of morbidly adherent placenta: expert review","volume":"213","author":"Fox","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20251007","first-page":"e1","article-title":"Placenta praevia and placenta accreta: diagnosis and management: green-top guideline no. 27a","volume":"126","author":"Jauniaux","year":"2019","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"R11-20251007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13256-015-0716-3","article-title":"Preservation of fertility and subsequent childbirth after methotrexate treatment of placenta percreta: a case report","volume":"9","author":"Tamate","year":"2015","journal-title":"J Med Case Reports"},{"key":"R12-20251007","first-page":"6408\u201311","article-title":"Single dose methotrexate in successful evacuation of second trimester placenta accreta","volume":"14","author":"Deshmukh","year":"2020","journal-title":"Indian J Forensic Med Toxicol"},{"key":"R13-20251007","first-page":"48\u201351","article-title":"Antenatal diagnosis of placenta increta and its successful conservative management with methotrexate","volume":"18","author":"G\u00fcler","year":"2013","journal-title":"East J Med"},{"key":"R14-20251007","first-page":"19\u201321","article-title":"Delayed and successful manual removal of abnormally adherent placenta necessitated by uterine sepsis following conservative management with adjuvant methotrexate - A rewarding clinical experience","volume":"19","author":"Shekhar","year":"2013","journal-title":"South Afr J Obstet Gynaecol"},{"key":"R15-20251007","doi-asserted-by":"crossref","first-page":"468\u201371","DOI":"10.1111\/aogs.12079","article-title":"Conservative management of abnormally invasive placenta: four case reports","volume":"92","author":"Ramoni","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R16-20251007","doi-asserted-by":"crossref","first-page":"1\u20133","DOI":"10.1186\/1757-1626-2-9349","article-title":"Preservation of fertility following abnormally adherent placenta treated conservatively: a case report","volume":"2","author":"Mahendru","year":"2009","journal-title":"Cases J"},{"key":"R17-20251007","doi-asserted-by":"crossref","first-page":"248\u201350","DOI":"10.1080\/00016340500486891","article-title":"Placenta accreta and methotrexate treatment","volume":"85","author":"Morken","year":"2006","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R18-20251007","first-page":"425\u201326","article-title":"Conservative management of placenta percreta: experiences in two cases","volume":"112","author":"Hays","year":"2008","journal-title":"Obstet Gynecol N Y 1953"},{"key":"R19-20251007","doi-asserted-by":"crossref","first-page":"299\u2013306","DOI":"10.1002\/ijgo.12411","article-title":"Conservative management of placenta percreta","volume":"140","author":"Matsuzaki","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"R20-20251007","first-page":"450\u201352","article-title":"High-dose methotrexate treatment in a breastfeeding mother with placenta accreta: a case report","volume":"13","author":"Baker","year":"2018","journal-title":"Breastfeed Med Off J Acad Breastfeed Med"},{"key":"R21-20251007","doi-asserted-by":"crossref","first-page":"214\u201317","DOI":"10.1111\/jcpt.13050","article-title":"Severe toxic effects of low\u2010dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations","volume":"45","author":"Tan","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R22-20251007","doi-asserted-by":"crossref","first-page":"952\u201355","DOI":"10.1016\/j.tjog.2020.09.027","article-title":"Successful treatment of placenta accreta spectrum disorder using management strategy of serial uterine artery embolization combined with standard weekly and a 8-day methotrexate\/folinic acid regimens at 7 weeks of gestation","volume":"59","author":"Chou","year":"2020","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R23-20251007","doi-asserted-by":"crossref","first-page":"378\u201383","DOI":"10.1016\/j.crad.2019.01.006","article-title":"Methotrexate infusion followed by uterine artery embolisation for the management of placental adhesive disorders: a case series","volume":"74","author":"Babaei","year":"2019","journal-title":"Clin Radiol"},{"key":"R24-20251007","doi-asserted-by":"crossref","first-page":"963\u201366","DOI":"10.1016\/j.placenta.2013.04.016","article-title":"Conservative management of morbidly adherant placenta - a case report and review of literature","volume":"34","author":"Khan","year":"2013","journal-title":"Placenta"},{"key":"R25-20251007","doi-asserted-by":"crossref","first-page":"7514\u201317","DOI":"10.1080\/14767058.2021.1951211","article-title":"The use of methotrexate in conservative treatment of placenta accreta spectrum disorders","volume":"35","author":"Gregoir","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R26-20251007","first-page":"80\u201384","article-title":"Successful conservative management of placenta accreta via embolization and methotrexate","volume":"55","author":"Subir\u00e1 Nadal","year":"2012","journal-title":"Prog Obstet Ginecol"},{"key":"R27-20251007","first-page":"127\u201329","article-title":"Conservative management of placenta previa percreta by leaving placental tissue in situ with arterial ligation and adjuvant methotrexate therapy","volume":"12","author":"Cirpan","year":"2011","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"R28-20251007","first-page":"981\u201382","article-title":"Failure of methotrexate and internal iliac balloon catheterization to manage placenta percreta","volume":"99","author":"Butt","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R29-20251007","first-page":"421\u201327","article-title":"High-intensity focused ultrasound combined procedures treatment of retained placenta accreta with marked vascularity after abortion or delivery","volume":"36","author":"Jiang","year":"2019","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"R30-20251007","first-page":"331\u201332","article-title":"Sequential methotrexate treatment with and estrogen and progestin in a retained adhesive placenta","volume":"37","author":"Mizuno","year":"2010","journal-title":"Clin Exp Obstet Gynecol"},{"key":"R31-20251007","doi-asserted-by":"crossref","first-page":"91\u201392","DOI":"10.1055\/s-2007-1004831","article-title":"Placenta percreta: methotrexate treatment and MRI findings","volume":"25","author":"Heiskanen","year":"2008","journal-title":"Am J Perinatol"},{"key":"R32-20251007","doi-asserted-by":"crossref","first-page":"162\u201363","DOI":"10.1016\/j.ijgo.2005.06.028","article-title":"Conservative treatment of placenta increta with methotrexate","volume":"91","author":"Crespo","year":"2005","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"key":"R33-20251007","doi-asserted-by":"crossref","first-page":"96\u201397","DOI":"10.1016\/S0301-2115(02)00241-5","article-title":"Conservative management of placenta accreta and unruptured interstitial cornual pregnancy using methotrexate","volume":"107","author":"Lalchandani","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:01:37Z","timestamp":1759827697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003524","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"2024-08-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}